What’s New

In light of a recent unfortunate incident involving the use of fat-derived stem cells to treat eye disease, we would like to use this blog post as an opportunity to explain the stem-cell procedures offered at RSI and emphasize the measures our team of physicians takes to maximize patient safety.

Last week, the New England Journal of Medicine released an article describing how three women suffered permanent eye damage after undergoing a procedure where fat-derived stem cells were injected into their eyes to treat macular degeneration. The incident was later featured in the New York Times. Such disturbing cases reveal the dangers of undergoing medical procedures performed by non-physicians in loosely-regulated settings.

At RSI, autologous cell procedures are used only to treat musculoskeletal conditions and all procedures are performed by licensed, board certified, specialty physicians who are trained in such interventional procedures. Moreover, our physicians only use stem-cells derived from the patient’s own bone marrow (and not from fat sources). While stem cells derived from patients’ fat have minimal clinical evidence of safety or efficacy, there is a growing body of clinical evidence proving the safety and efficacy of stem cells derived from a patient’s bone marrow.

Our mission at RSI is to place the needs of the patient above all others. This involves ensuring that all procedures offered at RSI are performed by the most qualified physicians who, in keeping abreast of the latest research, are able to offer their patients an evidence-based approach to care using only the safest and most effective regenerative procedures.